About

EpiEndo Pharmaceuticals is a privately held Icelandic pharmaceutical company developing a proprietary portfolio of compounds with epithelial barrier enhancing properties. EpiEndo is seed-funded, privately held and in preclinical development.

EpiEndo is focusing on chronic respiratory diseases. First clinical trials are planned for the year 2019.

EpiEndo is run as an international virtual organization coordinated by a team that consists of founding CEO Dr. Fridrik Runar Gardarsson and COO & CFO Birgir Magnusson, who coordinate a network of specialized service providers. 

Team

Dr. Fridrik Runar Gardarson
CEO & Founder

Fridrik Runar studied medicine at the University of Iceland, focusing on general medicine, paediatrics, anaesthesia and intensive care. 

 
 

Birgir Magnusson, M.Acc.
COO & CFO

Birgir has a background in finance and operations, consulting, auditing and has been on the board of numerous ventures. He is a graduate of the University of Iceland. 

 
 

Fredrik Lehman, PhD.
CMC Director

Fredrik has a PhD degree in Medicinal Chemistry from the University  of Gothenburg and has vast experience from various drug projects in different phases of development. In addition to being director of CMC, Fredrik holds the position as General Manager at Recipharm OT Chemistry AB (Uppsala, Sweden).

 

 
 

Karin von Wachenfeldt, PhD. 
Director of Pre-Clinical Development

Karin has over 20 years experience from the pharmaceutical industry, she specialises in pharmaceutical development of large and small molecules. She is a graduate of the University of Lund, Sweden and the CEO of Truly Labs in Sweden.

 

 

Board members

Professor Clive Page, OBE - Chairman

Birgir Magnusson

Hjalmar Skarphedinsson, PhD

Magnus Berg Magnusson

Dr. Olafur Baldursson

 

Scientific advisory board

Professor Gudmundur Hrafn Gudmundsson, University of Iceland

Professor Magnus Karl Magnusson, University of Iceland

Dr. Olafur Baldursson, University Hospital of Iceland

Dr. Sigurbergur Karason, University Hospital of Iceland

Professor Thorarinn Gudjonsson, University of Iceland

 

Latest updates

Collaboration

 
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761828

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 761828